Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy

Starting soon

Conditions studied: Lung Cancer (NSCLC)

In brief

The second-line treatment options in clinical practice for immunotherapy progress are complex. Treatment strategies need to be selected based on different progression patterns. It is difficult to simultaneously explore multiple treatment modalities through previous clinical studies. Observational studies through real-world research can efficiently convert clinical practice data into clinical treatment evidence. This study aims to observe the treatment patterns and clinical outcomes of advanced NSCLC patients who received first-line immunotherapy checkpoint inhibitor treatment after progression, in order to provide guidance for the second-line treatment options for patients with first-line immunotherapy progress.

Key facts

Study ID

NCT07596524

Run by

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

People needed

300

Starts

2026-07-01

Expected to finish

2027-06-30

Last updated by the study team

2026-05-19

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Locally advanced or metastatic NSCLC that is not curable and confirmed by histological or cytological examination based on the 8th edition of AJCC staging.
• Previously received advanced first-line treatment based on immune checkpoint inhibitor drugs.
• Has a medical record of disease progression during the first-line treatment.
• Complete clinical and pathological data, such as age, gender, smoking history, primary tumor location, differentiation, metastatic site, and imaging and serological review as required.

You may not qualify if…

• First-line treatment with immune checkpoint inhibitor drugs was ≤ 2 cycles.
• Excluding patients with incomplete key baseline and treatment information.
• Have other potential factors that may affect the study results or result in the premature discontinuation, as determined by the investigator

Where it is running

• Cancer Hospirtal, Chinese Academy of Medical Sciences — Beijing, Beijing Municipality, China
• Cancer Hospirtal, Chinese Academy of Medical Sciences, Shenzhen — Shenzhen, Guangdong, China
• Shanxi Provincial Cancer Hospital — Taiyuan, Shanxi, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.